Evoke Pharma, Inc.
EVOK · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.04 | 0.09 | -1.18 |
| FCF Yield | -8.51% | -14.23% | -18.88% | -12.29% |
| EV / EBITDA | 0.20 | 0.40 | 1.75 | -0.27 |
| Quality | ||||
| ROIC | -16.40% | -11.85% | -9.79% | -13.70% |
| Gross Margin | 95.53% | 98.65% | 96.42% | 96.08% |
| Cash Conversion Ratio | 0.45 | 0.36 | 0.76 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 49.69% | 53.03% | 58.70% | 59.86% |
| Free Cash Flow Growth | 43.36% | 19.56% | -51.47% | 0.24% |
| Safety | ||||
| Net Debt / EBITDA | 4.79 | 6.32 | 7.91 | 5.34 |
| Interest Coverage | -12.51 | -10.56 | -9.47 | -10.20 |
| Efficiency | ||||
| Inventory Turnover | 0.26 | 0.08 | 0.27 | 0.21 |
| Cash Conversion Cycle | -1,511.77 | -4,790.85 | -1,374.24 | -1,397.70 |